Amgen (AMGN) : Foster Dykema Cabot Co Incma reduced its stake in Amgen by 3.46% during the most recent quarter end. The investment management company now holds a total of 25,138 shares of Amgen which is valued at $4,349,377 after selling 900 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Amgen makes up approximately 0.98% of Foster Dykema Cabot Co Incma’s portfolio.
Other Hedge Funds, Including , Fil Ltd reduced its stake in AMGN by selling 10,522 shares or 1.36% in the most recent quarter. The Hedge Fund company now holds 763,053 shares of AMGN which is valued at $132,023,430. Amgen makes up approx 0.40% of Fil Ltd’s portfolio.Signature Estate Investment Advisors reduced its stake in AMGN by selling 73,446 shares or 96.44% in the most recent quarter. The Hedge Fund company now holds 2,714 shares of AMGN which is valued at $467,731. Amgen makes up approx 0.07% of Signature Estate Investment Advisors’s portfolio.Thompson Investment Management boosted its stake in AMGN in the latest quarter, The investment management firm added 9 additional shares and now holds a total of 27,687 shares of Amgen which is valued at $4,801,756. Amgen makes up approx 0.94% of Thompson Investment Management’s portfolio.P.r. Herzig boosted its stake in AMGN in the latest quarter, The investment management firm added 700 additional shares and now holds a total of 8,675 shares of Amgen which is valued at $1,437,187. Amgen makes up approx 2.87% of P.r. Herzig’s portfolio.Palisade Asset Management boosted its stake in AMGN in the latest quarter, The investment management firm added 825 additional shares and now holds a total of 35,238 shares of Amgen which is valued at $5,656,404. Amgen makes up approx 1.05% of Palisade Asset Management’s portfolio.
Amgen opened for trading at $174.44 and hit $175.99 on the upside on Tuesday, eventually ending the session at $174.4, with a gain of 0.03% or 0.05 points. The heightened volatility saw the trading volume jump to 23,76,437 shares. Company has a market cap of $130,514 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.